Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACCELERON PHARMA INC.

(XLRN)
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/15/2021 11/16/2021 11/17/2021 11/18/2021 11/19/2021 Date
173.5(c) 173.98(c) 179.68(c) 179.68(c) 178.75(c) Last
496 861 850 750 6 009 272 1 025 355 7 884 284 Volume
+0.23% +0.28% +3.28% 0.00% -0.52% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021
Net income 2021
Net Debt 2021
P/E ratio 2021
Yield 2021
Sales 2022 207 M - -
Net income 2022 -194 M - -
Net cash position 2022 14,7 M - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 10 932 M 10 932 M -
EV / Sales 2021
EV / Sales 2022 52,9x
Nbr of Employees 312
Free-Float 88,0%
More Financials
Company
Acceleron Pharma Inc. is a biopharmaceutical company. It is focused on discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on natural regulators of cellular growth and repair, mainly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. Its therapeutic areas include pulmonary and hematology. Its pulmonary program, Sotatercept, is a... 
More about the company
Ratings of Acceleron Pharma Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C+
More Ratings
All news about ACCELERON PHARMA INC.
11/22ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Biotechnology Index
CI
11/22ACCELERON PHARMA : Completion of Acquisition or Disposition of Assets - Form 8-K
PU
11/22ACCELERON PHARMA INC : Completion of Acquisition or Disposition of Assets, Notice of Delis..
AQ
11/22Merck Completes Acceleron Pharma Acquisition
MT
11/22Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
AQ
11/22Merck Completes Cash Tender Offer to Purchase Acceleron Pharma at $180/Share
MT
11/22ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Composite Index
CI
11/22ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P Global BMI Index
CI
11/22ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P TMI Index
CI
11/22ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P Biotechnology Select Industry Inde..
CI
11/19Merck Completes Tender Offer to Acquire Acceleron Pharma Inc
CI
11/19Merck Sharp & Dohme Corp. completed the acquisition of Acceleron Pharma Inc. from Avoro..
CI
11/17Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's 'Inadequate' Offe..
MT
11/17Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer
BU
11/17Merck Extends Tender Offer for Acceleron Pharma
MT
More news
News in other languages on ACCELERON PHARMA INC.
11/22MERCK : l'acquisition d'Acceleron est finalisée
11/22Merck conclut l'acquisition d'Acceleron Pharma
11/22Merck conclut une offre publique d'achat en espèces visant à acquérir Acceleron Pharma ..
11/17MERCK : l'OPA sur Acceleron va être prolongée
11/17Merck prolonge son offre publique d'achat sur Acceleron Pharma
More news
Analyst Recommendations on ACCELERON PHARMA INC.
More recommendations
Chart ACCELERON PHARMA INC.
Duration : Period :
Acceleron Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACCELERON PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Habib J. Dable President, Chief Executive Officer & Director
Kevin F. McLaughlin Chief Financial Officer, Treasurer & Senior VP
Francois Nader Non-Executive Chairman
Ravindra Kumar Chief Scientific Officer & Senior Vice President
Jay T. Backstrom Executive VP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ACCELERON PHARMA INC.39.71%10 932
GILEAD SCIENCES, INC.21.27%88 622
BIONTECH SE344.70%87 556
REGENERON PHARMACEUTICALS35.46%68 421
WUXI APPTEC CO., LTD.27.38%66 062
VERTEX PHARMACEUTICALS-19.56%48 336